Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Drops By 6.4%

Biodesix, Inc. (NASDAQ:BDSX) was the recipient of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 388,900 shares, a drop of 6.4% from the October 31st total of 415,700 shares. Based on an average trading volume of 387,700 shares, the short-interest ratio is presently 1.0 days.

Insider Buying and Selling

In related news, Director Jack W. Schuler bought 200,000 shares of Biodesix stock in a transaction dated Wednesday, November 20th. The shares were acquired at an average cost of $1.17 per share, with a total value of $234,000.00. Following the completion of the transaction, the director now owns 31,094,935 shares in the company, valued at $36,381,073.95. The trade was a 0.65 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Matthew Strobeck purchased 40,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was purchased at an average price of $1.40 per share, with a total value of $56,000.00. Following the acquisition, the director now directly owns 2,606,879 shares of the company’s stock, valued at $3,649,630.60. This trade represents a 1.56 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders acquired 315,000 shares of company stock valued at $393,500. Insiders own 69.20% of the company’s stock.

Institutional Trading of Biodesix

A number of institutional investors have recently made changes to their positions in the business. Barclays PLC increased its position in Biodesix by 1,140.5% during the 3rd quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after buying an additional 21,179 shares in the last quarter. CVI Holdings LLC acquired a new stake in Biodesix in the second quarter worth about $59,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Biodesix during the third quarter worth about $262,000. Geode Capital Management LLC increased its holdings in shares of Biodesix by 50.7% during the third quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock valued at $1,433,000 after acquiring an additional 270,724 shares in the last quarter. Finally, Perkins Capital Management Inc. raised its position in shares of Biodesix by 74.7% in the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after purchasing an additional 310,000 shares during the last quarter. Institutional investors and hedge funds own 20.96% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Scotiabank assumed coverage on shares of Biodesix in a research report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $3.06.

Biodesix Stock Down 5.6 %

BDSX stock traded down $0.08 during trading on Monday, reaching $1.36. 148,753 shares of the company traded hands, compared to its average volume of 208,768. The company has a market capitalization of $197.84 million, a price-to-earnings ratio of -3.69 and a beta of 1.22. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. The business has a 50 day simple moving average of $1.53 and a 200 day simple moving average of $1.60. Biodesix has a 12 month low of $1.11 and a 12 month high of $2.21.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings data on Friday, November 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $18.15 million for the quarter, compared to the consensus estimate of $18.45 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. During the same quarter in the previous year, the firm earned ($0.12) EPS. On average, equities research analysts anticipate that Biodesix will post -0.35 earnings per share for the current fiscal year.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.